deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03168061

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma

Sponsor: NanoCarrier Co., Ltd.

Conditions Metastatic Sarcoma Sarcoma Soft Tissue Sarcoma Solid Tumor
Interventions NC 6300
Updated 11 times since 2017 Last updated: Feb 27, 2020 Started: Jun 30, 2017 Primary completion: Jul 31, 2020 Completion: Jul 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Metastatic Sarcoma and Sarcoma, this trial is ongoing. The trial is conducted by NanoCarrier Co., Ltd. and has accumulated 11 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshotNot Yet Recruiting~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshotRecruiting~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotRecruiting~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotRecruiting~Oct 2018 – ~Mar 2020 · 17 months · monthly snapshotRecruiting~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshotRecruiting~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshotRecruiting~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Recruiting → Unknown Status

  5. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Oct 2018 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2017 — Jan 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Jul 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NanoCarrier Co., Ltd.
Data source: NanoCarrier Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations